Pantherics Incorporated

Pantherics Incorporated is on the forefront of developing novel drugs based on targeting GABA receptors in the lung and other peripheral organs. The company’s lead product is an oral medication for symptom control in persistent asthma and is based on technology licensed from UW-Milwaukee Research Foundation and Columbia University. Pantherics seeks to fund a MIDD Fellowship for an advanced PhD student engaged in original, translational drug discovery research.